CClinicalTrials.gg
CompletedNCT04516473BCSPUpdated Jan 20, 2022

The Impact of Abdominal Body Contouring Surgery on Physical Function After a Massive Weight Loss (BCSP)

An observational study in Weight Loss and Obesity, sponsored by University of British Columbia. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-01-20.

Sponsored by University of British Columbia · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
27
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Obesity is a growing chronic medical condition in which as of 2015, a total of 107.7 million children and 603.7 million adults were considered obese and since 1980 the prevalence of obesity has doubled in more than 70 countries. It is estimated that 70 percent of individuals who undergo a massive weight loss would develop excess skin and based on patient reported outcome measures, it has been shown that excess skin negatively impacts patients' body image, self-esteem, physical function and body contouring surgeries have been demonstrated to improve these measures. These are surgeries that correct for excess skin and its adverse consequences. The form of the surgery is case dependent and can range from removing an apron of skin to complete contouring of the abdomen with tightening of the abdominal muscle and moving the belly button. Despite previous studies indicating mobility limitation because of excess skin and improvements after abdominal body contouring surgeries with the use of subjective measures of physical function, there are no studies that directly measures physical fitness post body contouring surgeries. Therefore, the purpose of the current study is to evaluate the impact of abdominal body contouring surgeries on direct objective measures of physical function.

It is hypothesized that 1) the removal of excess skin will improve direct objective measures of physical function in post massive weight loss participants 2) the removal of excess skin will improve direct measures of gait and balance in post massive weight loss participants 3) the removal of excess skin will improve patient reported outcome measures using quality of life questionnaires in post massive weight loss participants 4) the removal of excess skin will improve aerobic capacity in post massive weight loss participants 5) the removal of excess skin does not change the body composition in post massive weight loss participants.

Read the detailed description

Participants will be recruited through multiple medical clinics and will visit the exercise, nutrition and muscle metabolism lab twice over the course of 8-12 weeks to complete objective and subjective measures of physical function. Each testing session will be conducted by the study investigator and physical function testing will be video recorded to reduce measurer bias. Based on participants' status they will be allocated to either a body contouring intervention group (BCI) or a post massive weight loss matched control (PMWMC). The first testing session would happen preoperatively and second one would happen between 8-12 weeks postoperatively depending on recovery required. Pain levels will be measured both pre and postoperatively using a numerical rating scale (0-10) to ensure adequate recovery.

Outcomes will include a variety of objective measures of physical function including 9-item modified physical performance test (mPPT), 30 second chair stand, timed up and go, stair climbing power, modified agility t-test, star excursion balance test, and 6 minute walk test. A body composition measure consisting of fat mass and fat free mass will also be obtained via dual-energy X-ray absorptiometry. Subjective measures would include 6 components of health related quality of life measure using BODY-Q questionnaire that would include sub scales such as body image, physical function, psychological, sexual, social, and obesity symptoms. Other subjective measure would include rate of perceived exertion which would be measured during each of the objective tests.

Additionally, grade of excess skin would be measured by images provided to the participants and weight of the resected excess skin will be obtained from the operating surgeon at the end of the study.

To obtain demographic history, physical activity level post surgery and to gain feedback for future clinical trial, the participants will also complete a socioeconomic status questionnaire, physical activity questionnaire, and participant experience with research questionnaire.

02

Conditions studied

  • Weight Loss
  • Obesity

Keywords

  • Panniculectomy
  • Excess Skin
03

In context

Body Weight

1,223 studies on the registry are indexed under Body Weight; 131 are open to participants now.

This study's enrollment of 27 is below the median of 140 across 238 observational studies indexed under Body Weight.

Browse Body Weight studies →

Lead sponsor

University of British Columbia is the lead sponsor of 1,309 studies on the registry; 253 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Male and female who have undergone a massive weight loss through any weight loss intervention, have excess skin, are healthy enough to perform simple physical function tasks and self-selected to undergo abdominal skin removal surgery.

Participants who have similar criteria to the intervention group but will not undergo surgical intervention during the course of the study will serve as a control group.

Inclusion criteria

  • Weight has not deviated by greater than 5 percent for 3 months
  • Have excess grade skin of greater or equal to 2
  • Percent total weight loss pre-body contouring of greater or equal to 25 percent
  • Fluently read and write English

Exclusion criteria

Exclusion Criteria:

  • Any musculoskeletal issues that would prevent participants from doing the physical function tests.
  • Current medication history indicating atypical antipsychotics including but not limited to clozapine, olanzapine, quetiapine, risperidone, aripiprazole, amisulpride, ziprasidone, asenapine, iloperidone, lurasidone and paliperidone.
  • Severe pulmonary conditions such as severe chronic obstructive pulmonary disease (COPD) and or severe asthma.
  • Participants who actively aiming to lose weight
  • Have diabetes with diabetic neuropathy or experienced hypoglycemic event within 6 months prior to the study
  • Severe kidney disease with estimated glomerular filtration rate (eGFR) less than 60 ml/min
  • Pregnant individuals
  • Uncontrolled hypertension with resting blood pressure greater than 160/90 mmHg
  • Uncontrolled obstructive sleep apnea with symptoms
  • On statin therapy with myopathy
  • Unstable atrial fibrillation
  • Weight pre-body contouring greater than 340 lbs (154 kg)
  • Current smoker
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
27 participants (actual)
Patient registry
No

Groups and cohorts

  • Experimental/Body Contouring Intervention

    These are participants who have self-selected to undergo an abdominal body contouring procedure within the course of the study.

    Procedure: Abdominal Body Contouring

  • Control/Post Massive Weight Loss Matched Control

    These are participants who have similar characteristics to the body contouring intervention group, but they will not undergo any surgical procedure during the course of the study. The addition of this matched control group with a similar degree of excess skin but who will not be undergoing body contouring surgery will control for any changes in physical function which may occur without any intervention within the testing sessions. This group will also control for any learning effects between testing sessions.

Interventions

  • ProcedureAbdominal Body Contouring

    These are surgeries that correct for excess skin and its adverse consequences. The surgeries that focus on central area to remove a large hanging pannus is usually called panniculectomies or abdominoplasties; the former is focused on the excision of excess tissue to relieve impairment while the latter is generally considered a cosmetic surgery. The form of the surgery is case dependent and can range from removing apron of skin to complete contouring of the abdomen with tightening of the abdominal muscle and moving the belly button.

06

What researchers measure

Primary outcomes

  1. Change in physical function aggregate score

    Measured by 9-item modified physical performance test that gives an aggregate score out 36 and comprises of 9 tests pre and post surgery and includes the following: 1. Time to complete a book lift 2. Time to complete putting on/off a lab coat 3. Time to complete picking up a penny from the floor 4. Time to complete a 5 times chair stand 5. Turning 360 degrees 6. Time to complete a 50 feet walk 7. Time to complete 1 flight of stairs 8. Completing 4 flights of stairs 9. A progressive romberg test Lowest score is 0, highest score is 36 and higher scores represent better outcomes.

    Time frame: 8-12 weeks

Secondary outcomes

  1. Change in lower body strength

    Measured by number of stands completed during a 30 seconds chair stand pre and post surgery

    Time frame: 8-12 weeks

  2. Change in time to complete agility drill

    Measured by time to complete a modified agility t-test pre and post surgery

    Time frame: 8-12 weeks

  3. Change in timed up and go

    Measured by time to complete a timed up and go test

    Time frame: 8-12 weeks

  4. Change in stair climbing power

    Measured by time to ascend 10 stairs and deriving power pre and post surgery

    Time frame: 8-12 weeks

  5. Change in dynamic balance balance

    Measured by star excursion balance test pre and post surgery

    Time frame: 8-12 weeks

  6. Change in aerobic capacity

    Measured by distance traveled during a 6 minute walk test pre and post surgery

    Time frame: 8-12 weeks

  7. Change in lean body mass

    Measured by change in bone free fat mass by using dual-energy X-ray absorptiometry pre and post surgery

    Time frame: 8-12 weeks

  8. Change in fat mass

    Measured by using dual-energy X-ray absorptiometry pre and post surgery

    Time frame: 8-12 weeks

  9. Change in patient reported outcome measure of physical function and quality of life

    Measured by 6 health related quality of life components of BODY-Q questionnaire pre and post surgery. Sub-scales would include body image, physical function, psychological, sexual, social, and obesity/physical symptoms. Each sub-scale will be graded individually, and the raw scores will be converted into a score from 0-100. For body image, physical function, psychological function, sexual, and social function higher scores represent a better outcome For obesity/physical symptoms, symptoms will be added so that the total number of symptoms experienced would be obtained. Minimum number of symptoms is 0 and maximum is 10.

    Time frame: 8-12 weeks

  10. Change in rate of perceived exertion (RPE) during physical function tests

    Measured by BORG RPE scale pre and post surgery. Minimum score is 6 and maximum is 20. The scale is only to provide how much the participants are being exerted when given a task.

    Time frame: 8-12 weeks

Other outcomes

  1. Correlation between degree of excess skin and change in objective physical function test scores

    Measured by linear models and correlating the degree of excess skin and change in measures of physical function scores from post to pre surgery

    Time frame: 8-12 weeks

  2. Correlation between the weight of resected excess skin and change in objective physical function tests

    Measured by linear models and correlating the amount of weight of the resected excess skin and change in measures of physical function scores from post to pre surgery

    Time frame: 8-12 weeks

07

Study locations

1 site
  • University of British Columbia
    Vancouver, British Columbia V6T 1Z3, Canada
08

References and documents

Individual participant data

Plan to share: No — No plan available for IPD sharing

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04516473
Lead sponsor
University of British Columbia
Responsible party
Cameron Mitchell (Assistant Professor, University of British Columbia) — Principal investigator
First posted
Aug 18, 2020
Start date
Aug 18, 2020
Primary completion
Dec 29, 2021
Completion
Dec 29, 2021
Last update
Jan 20, 2022

Study contacts

Cameron Mitchell, PhD
principal investigator · Assistant Professor University of British Columbia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion